Rhesus macaques previously infected with simian/human immunodeficiency virus are protected from vaginal challenge with pathogenic SIVmac239
- PMID: 9032322
- PMCID: PMC191267
- DOI: 10.1128/JVI.71.3.1911-1921.1997
Rhesus macaques previously infected with simian/human immunodeficiency virus are protected from vaginal challenge with pathogenic SIVmac239
Abstract
Nontraumatic vaginal inoculation of rhesus macaques with a simian/human immunodeficiency virus (SIV/HIV) chimera containing the envelope gene from HIV-1 89.6 (SHIV 89.6) results in systemic infection (Y. Lu, B. Brosio, M. Lafaile, J. Li, R. G. Collman, J. Sodroski, and C. J. Miller, J. Virol. 70:3045-3050, 1996). A total of five rhesus macaques have each been infected by exposure to at least three intravaginal inoculations of SHIV 89.6. The SHIV 89.6 infection is characterized by a transient viremia that evokes humoral and cellular immune responses to HIV and SIV antigens, but disease does not develop in animals infected with SHIV 89.6. To determine if a previous infection with SHIV 89.6 by vaginal inoculation could protect animals from vaginal challenge with pathogenic SIV, all five animals were intravaginally inoculated twice with pathogenic SIV-mac239. After challenge, all of the SHIV-immunized animals had low or undetectable viral RNA levels in plasma compared to control animals. Three of the five of the SHIV-immunized animals remained virus isolation negative for more than 8 months, while two became virus isolation positive. The presence of SIV Gag-specific cytotoxic T lymphocytes in peripheral blood mononuclear cells and SIV-specific antibodies in cervicovaginal secretions at the time of challenge was associated with resistance to pathogenic SIV infection after vaginal challenge. These results suggest that protection from sexual transmission of HIV may be possible by effectively stimulating both humoral and cellular antiviral immunity in the systemic and genital mucosal immune compartments.
Similar articles
-
In vivo replication capacity rather than in vitro macrophage tropism predicts efficiency of vaginal transmission of simian immunodeficiency virus or simian/human immunodeficiency virus in rhesus macaques.J Virol. 1998 Apr;72(4):3248-58. doi: 10.1128/JVI.72.4.3248-3258.1998. J Virol. 1998. PMID: 9525652 Free PMC article.
-
Targeted lymph-node immunization with whole inactivated simian immunodeficiency virus (SIV) or envelope and core subunit antigen vaccines does not reliably protect rhesus macaques from vaginal challenge with SIVmac251.AIDS. 1998 Jan 1;12(1):1-10. doi: 10.1097/00002030-199801000-00001. AIDS. 1998. PMID: 9456249 Free PMC article.
-
Efficacy of a SHIV 89.6 proviral DNA vaccine against mucosal SIVmac239 challenge.Vaccine. 2005 Jul 1;23(31):4036-47. doi: 10.1016/j.vaccine.2005.03.013. Epub 2005 Apr 9. Vaccine. 2005. PMID: 15963361
-
Antiviral CD8+ T cells in the genital tract control viral replication and delay progression to AIDS after vaginal SIV challenge in rhesus macaques immunized with virulence attenuated SHIV 89.6.J Intern Med. 2009 Jan;265(1):67-77. doi: 10.1111/j.1365-2796.2008.02051.x. J Intern Med. 2009. PMID: 19093961 Free PMC article. Review.
-
Vaccine-induced V1V2-specific antibodies control and or protect against infection with HIV, SIV and SHIV.Curr Opin HIV AIDS. 2019 Jul;14(4):309-317. doi: 10.1097/COH.0000000000000551. Curr Opin HIV AIDS. 2019. PMID: 30994501 Free PMC article. Review.
Cited by
-
Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen.J Virol. 1999 Sep;73(9):7524-32. doi: 10.1128/JVI.73.9.7524-7532.1999. J Virol. 1999. PMID: 10438842 Free PMC article.
-
High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection.J Virol. 2009 Apr;83(7):3288-97. doi: 10.1128/JVI.02423-08. Epub 2009 Jan 7. J Virol. 2009. PMID: 19129448 Free PMC article.
-
Innate protection against intrarectal SIV acquisition by a live SHIV vaccine.JCI Insight. 2024 May 21;9(12):e175800. doi: 10.1172/jci.insight.175800. JCI Insight. 2024. PMID: 38912579 Free PMC article.
-
Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251.J Virol. 1999 Sep;73(9):7430-40. doi: 10.1128/JVI.73.9.7430-7440.1999. J Virol. 1999. PMID: 10438833 Free PMC article.
-
Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors.J Virol. 2001 Aug;75(16):7435-52. doi: 10.1128/JVI.75.16.7435-7452.2001. J Virol. 2001. PMID: 11462016 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous